Neurosteroid

Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors.[1][2] The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain.[3][4] The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function.[5][6] The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy[7] and traumatic brain injury.[8][9] Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.[10]
Classification
[edit]Based on differences in activity and structure, neurosteroids can be broadly categorized into several different major groupings.[3]
Inhibitory neurosteroids
[edit]These neurosteroids exert inhibitory actions on neurotransmission. They act as positive allosteric modulators of the GABAA receptor (especially δ subunit-containing isoforms), and possess, in no particular order, antidepressant, anxiolytic, stress-reducing, rewarding,[11] prosocial,[12] antiaggressive,[13] prosexual,[12] sedative, pro-sleep,[14] cognitive and memory-impairing,[citation needed] analgesic,[15] anesthetic, anticonvulsant, neuroprotective, and neurogenic effects.[3]
Major examples include tetrahydrodeoxycorticosterone (THDOC), the androstane 3α-androstanediol, the cholestane cholesterol and the pregnanes pregnanolone (eltanolone), allopregnanolone (3α,5α-THP).[16][17]
Excitatory neurosteroids
[edit]These neurosteroids have excitatory effects on neurotransmission. They act as potent negative allosteric modulators of the GABAA receptor, weak positive allosteric modulators of the NMDA receptor, and/or agonists of the σ1 receptor, and mostly have antidepressant, anxiogenic, cognitive and memory-enhancing, convulsant, neuroprotective, and neurogenic effects.[3]
Major examples include the pregnanes pregnenolone sulfate (PS), epipregnanolone, and isopregnanolone (sepranolone), the androstanes dehydroepiandrosterone (DHEA; prasterone), and dehydroepiandrosterone sulfate (DHEA-S; prasterone sulfate), and the cholestane 24(S)-hydroxycholesterol (NMDA receptor-selective; very potent).[18]
Pheromones
[edit]Pheromones are neurosteroids that influence brain activity, notably hypothalamic function, via activation of vomeronasal receptor cells.[19][20][21]
Possible human pheromones include the androstanes androstadienol, androstadienone, androstenol, and androstenone and the estrane estratetraenol.
Other neurosteroids
[edit]Certain other endogenous steroids, such as pregnenolone,[22] progesterone,[23][24] estradiol,[6] and corticosterone are also neurosteroids. However, unlike those listed above, these neurosteroids do not modulate the GABAA or NMDA receptors, and instead affect various other cell surface receptors and non-genomic targets. Also, many endogenous steroids, including pregnenolone, progesterone, corticosterone, deoxycorticosterone, DHEA, and testosterone, are metabolized into (other) neurosteroids, effectively functioning as so-called proneurosteroids.
Biosynthesis
[edit]Neurosteroids are synthesized from cholesterol, which is converted into pregnenolone and then into all other endogenous steroids. Neurosteroids are produced in the brain after local synthesis or by conversion of peripherally-derived adrenal steroids or gonadal steroids. They accumulate especially in myelinating glial cells, from cholesterol or steroidal precursors imported from peripheral sources.[25][26] 5α-reductase type I and 3α-hydroxysteroid dehydrogenase are involved in the biosynthesis of inhibitory neurosteroids, while 3β-hydroxysteroid dehydrogenase and hydroxysteroid sulfotransferases are involved in excitatory neurosteroid production.[3]
Biological Function
[edit]Some major known biological functions of neurosteroids include modulation of neural plasticity,[27] learning and memory processes,[28] behavior,[29][30] and seizure susceptibility,[31] as well as responses to stress, anxiety, and depression.[12][32] Neurosteroids also appear to play an important role in various sexually-dimorphic behaviors and emotional responses.[30]
Acute stress elevates the levels of inhibitory neurosteroids like allopregnanolone, and these neurosteroids are known to counteract many of the effects of stress.[33] This is similar to the case of endorphins, which are released in response to stress and physical pain and counteract the negative subjective effects of such states. As such, it has been suggested that one of the biological functions of these neuromodulators may be to help maintain emotional homeostasis.[29][34] Chronic stress has been associated with diminished levels of allopregnanolone and altered allopregnanolone stress responsivity, psychiatric disorders, and hypothalamic-pituitary-adrenal axis dysregulation.[32][33]
It is thought that fluctuations in the levels of inhibitory neurosteroids during the menstrual cycle and pregnancy play an important role in a variety of women's conditions, including premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), postpartum depression (PPD), postpartum psychosis, and catamenial epilepsy.[35][36][37] In addition, it is thought that changes in neurosteroid levels may be involved in the changes in mood, anxiety, and sexual desire that occur during puberty in both sexes and during menopause in women.[3][38][39]
Elevated levels of inhibitory neurosteroids, namely allopregnanolone, can produce paradoxical effects, such as negative mood, anxiety, irritability, and aggression.[40][41][42][43] This appears to be because these neurosteroids, like other positive allosteric modulators of the GABAA receptor such as the benzodiazepines, barbiturates, and ethanol,[35][43] possess biphasic, U-shaped actions – moderate levels (in the range of 1.5–2 nM/L total alloprogesterone, which are approximately equivalent to luteal phase levels) inhibit the activity of the GABAA receptor, while lower and higher concentrations facilitate the activity of the receptor.[41][42]
Molecular mechanism and translational developments
[edit]Biological importance and functions in maintaining homeostasis
[edit]Neurosteroids are important endogenous regulators of brain function. Through interactions with neuronal receptors and neurotransmitter systems, they affect nerve cell excitability, synaptic transmission, and the integration of neural networks. Neurosteroids are now recognized as the main modulators of brain physiology and pathology.[44][45] Of particular importance is their modulating effect on the balance between inhibitory and excitatory neurotransmission, in which γ-aminobutyric acid (GABA), glutamate and other neurotransmitter systems are particularly involved. Neurosteroids also contribute to the regulation of stress responses, activity of the hypothalamic-pituitary-adrenocortical (HPA) axis, emotional behavior and cognitive processes.[46] Their effects are not limited to neurotransmission, but also include the regulation of neuroinflammatory processes, nerve cell survival, neurogenesis and myelination.[47] Thanks to their dynamic adaptation to physiological conditions and environmental stimuli, these substances contribute to the maintenance of neuronal homeostasis and adaptation of the central nervous system. Changes in their synthesis, metabolism or receptor-mediated signaling are associated with disorders of these regulatory processes and increased susceptibility to various psychiatric and neurological disorders.[48]
Historical milestones in neurosteroid research
[edit]The history of neurosteroid research can be traced through several major discoveries. In 1938, Beall and Reichstein isolated 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) from adrenal tissue during investigations of peripheral steroid metabolism, without knowledge of its neurological activity.[49] In 1941, Hans Selye demonstrated that steroid hormones could produce rapid anesthetic effects in experimental animals, providing early evidence of their neuroactive properties. [50] A further breakthrough came in 1981, when Corpéchot et al. identified steroid compounds in the brain at concentrations suggesting local synthesis independent of peripheral endocrine glands, helping establish the concept of neurosteroids.[51]
Between 1984 and 1986, electrophysiological and biochemical studies connected steroid action to the GABAA receptor system. Harrison and Simmonds (1984) [52] demonstrated positive modulation of GABA receptor function by the steroid anesthetic alphaxalone, while Majewska et al. (1985, 1986) investigated glucocorticoid modulation and demonstrated the potent effects of endogenous steroid metabolites, including allopregnanolone, on the GABA receptor–chloride channel complex. [53][54] These discoveries established the foundations for subsequent research into neurosteroid biosynthesis, receptor-binding sites, physiological functions and therapeutic applications. In later publications, Majewska and Schwartz emphasized that the discovery of steroid modulation of GABAergic neurotransmission opened new directions for research into the neurobiological basis of numerous psychophysiological phenomena. [55] They suggested (1987) that this mechanism of steroid neuroactivity might be relevant to stress, depression, anxiety, aggression and memory, as well as to conditions such as postpartum depression and premenstrual tension. [56] These suggestions helped establish a broader research agenda extending from molecular neurochemistry to behavioral and psychiatric processes.
Molecular Brain function of neurosteroids
[edit]Beginning in the late 1970s, Baulieu with collaborators at INSERM investigated the presence and metabolism of steroid hormones in the central nervous system. In a series of studies published between 1978 and 1981, they demonstrated that pregnenolone, dehydroepiandrosterone (DHEA), and related steroids are synthesized de novo in the brain, independently of peripheral endocrine glands. In 1981 Baulieu introduced the term “neurosteroids” to describe these endogenously produced steroids with potential neuromodulatory actions.[57] During the early 1980s Baulieu’s group catalogued the distribution of neurosteroids in different brain regions and documented their variation across age, stress, and physiological states.[58][59] At that time Baulieu believed that, although neurosteroids were clearly present in the central nervous system, their mechanism of action in neuroactivity and physiological function remained unknown.[60]
Mechanistic Fundamentals
A further advance occurred in 1986, when Majewska, Harrison et al. at NIMH reported that allopregnanolone and related neurosteroids are potent positive modulators of the GABAA receptor.[1] This work provided the first molecular mechanism for neurosteroid action and established a direct link between Baulieu’s discovery of brain-derived steroids and inhibitory neurotransmission. This was followed by the groups' research throughout the late 1980s and 1990s, that expanded the concept of neurosteroid modulation of GABAergic signaling and its relevance to stress, anxiety, seizure susceptibility, and mood regulation.[61][62][63][64][65][66][67] NIMH acknowledged the importance of this basic research for the first therapeutics 40 years later:[68]
Taking allopregnanolone from bench to bedside: Brexanolone, first-ever drug specifically designed for postpartum depression, later discontinued, was created as a development of a series of basic and translational neuroscience studies, that began in the NIMH Intramural Research Program (IRP).[69] [70] From neurobiology through translational science and into biomarker-guided mechanistic clinical trials – this was NIMH’s drug development approach, with the discovery of the allopregnanolone brain function as an exemplary case.[71]
Neurosteroid binding sites on GABAA receptors
[edit]Neurosteroids work through two main pathways:
1. Rapid, non-genomic effects: positive modulation of GABAA receptors, i.e. anxiolytic, anticonvulsant, and sedative modulation of NMDA receptors. Stimulant effect on signaling pathways. Examples of such neurosteroids: allopregnanolone (3α,5α THP) THDOC (3α,5α THDOC), pregnenolone (3α,5β THP). Antagonistic neurosteroids: pregnanolone sulfate, DHEAS.
2. Slow, genomic effects affect gene expression via classical steroid receptors.
Neurosteroids modulate GABAA receptors by binding to multiple sites within their transmembrane domains.[72] A major advance was the identification of a canonical intersubunit binding site at the interface between α and β subunits, where positive allosteric modulators such as allopregnanolone and tetrahydrodeoxycorticosterone (THDOC) enhance GABA-induced chloride currents. [73]
At higher concentrations, some neurosteroids can also directly activate the receptor in the absence of GABA. Subsequent studies using photoaffinity labeling, mutagenesis and structural methods, including cryogenic electron microscopy (cryo-EM), identified additional intrasubunit binding sites and revealed that different sites can produce distinct effects on receptor function, including potentiation, direct activation and desensitization. [74][75][76] These sites are highly conserved throughout the GABAA receptor family, and their identification provides a unique opportunity for the development of new therapeutic, neurosteroid-based ligands and transgenic disease models of neurosteroid dysfunction. Sulfated neurosteroids, such as pregnenolone sulfate, can inhibit GABA<sub receptor activity through mechanisms distinct from those of positive modulators. Recent structural and direct-binding studies have further characterized these interactions and their allosteric relationships. [77] Although the precise contributions of individual binding sites in different native receptor subtypes remain under investigation, their identification has provided an important molecular foundation for understanding neurosteroid action and developing neuroactive steroid therapeutics.
Development of neurosteroid-based therapeutics
[edit]The discovery of neurosteroid modulation of GABAA receptors stimulated research into their potential therapeutic applications in neurological and psychiatric disorders.[78] In the early 21st century, the neurosteroid field developed into a translational research area in neuropsychopharmacology. [79][80][81][82][83] Later it was demonstrated that brain allopregnanolone levels are regulated by stress and can be altered independently of peripheral steroid production [84][85], providing a clinical rationale for investigating neurosteroid-based treatments. Preclinical studies also demonstrated anxiolytic and antidepressant-like effects of allopregnanolone, while research into the hormonal changes accompanying pregnancy and childbirth suggested a possible role for postpartum neurosteroid withdrawal in postpartum depression.[86]
These results led to the development of Brexanolone, an intravenous formulation of allopregnanolone, which showed rapid antidepressant effects in phase II and III clinical trials [87] and was approved by the US Food and Drug Administration (FDA) in 2019 for postpartum depression.[88] A further development was Zuranolone, an orally active synthetic neuroactive steroid and positive allosteric modulator of GABAA receptors, approved by the FDA in 2023 for postpartum depression.[89] In 2025 Zuranolone was approved in Japan for major depressive disorder and depressive states, following a Japanese phase III clinical trial.[90] These developments represent a transition from basic research on endogenous neurosteroids to clinically established neuroactive steroid therapeutics.[91]
Postpartum depression
[edit]After discontinuation of Brexanolone, an intravenous formula of allopregnanolone, Zuranolone, an oral synthetic analogue, received FDA approval in 2023 as the first oral therapy for PPD. In the US and Europe, Zuranolone is approved for the treatment of PPD in adult women; in Canada, it is approved for the treatment of moderate to severe PPD.[92] Clinical studies show that Zuranolone can cause a significant reduction in symptoms of depression within 15 days, which lasts up to 45 days after treatment ends. A recent meta-analysis of seven randomized controlled trials concludes that Zuranolone is a fast-acting and well-tolerated treatment for PPD and major depressive disorder. [93] As for the indication for MDD, the FDA's final decision is still pending.
Brexanolone and Zuranolone are recognized as examples of successful development "from laboratory workbench to the patient's bedside", in which clinical observations of hormonal mood swings have been combined with mechanistic results of neurosteroid research. These developments show how advances in central nervous system therapy are based on many years of basic research in receptor biology, neurochemistry, and disease mechanisms. [94][95][96][97][98][99]
Neurosteroids in Major Depression
[edit]Zuranolone was approved by the FDA in the United States in 2023 for the treatment of postpartum depression only. The agency rejected approval for Major Depression Disorder (MDD) (Complete Response Letter). Common side effects include drowsiness, dizziness, sedation, headache, and nausea. [100] In Japan, zuranolone (brand name ZURZUVAE) received approval for depression and depressive states (including MDD) in December 2025. The basis was a positive phase III trial in Japan that took 30 mg once daily for 14 days, which showed significant and early improvement in symptoms and the possibility of re-treatment after a break of at least six weeks.[101][102][103][104][105]
Therapeutic significance of neurosteroids and future prospects
[edit]Awareness that neurosteroids are involved in the regulation of neuronal and neuroimmune homeostasis has spurred the development of therapeutics targeting these pathways.[106][107] These advances represent important milestones in translating years of research on endogenous neurosteroid signaling into clinical applications. In addition, preclinical and clinical studies are investigating the therapeutic potential of neurosteroid-based therapies in a wider range of psychiatric and neurological disorders, including major depression, bipolar disorder, anxiety disorders, post-traumatic stress disorder, epilepsy, and neurodegenerative diseases.[108]
Future research will focus on identifying biomarkers of neurosteroid dysregulation, developing more selective drugs, optimizing their pharmacological properties, and identifying patient populations most likely to benefit from such treatments.[109] A better understanding of the interactions between neurosteroid signaling pathways, neuronal excitability, stress regulation, and neuroinflammation may open up further therapeutic opportunities, especially therapeutic approaches to restore impaired neuronal homeostasis.[110] Although many of these applications are still being studied, neurosteroid-based neurosteroid pharmacology has emerged as a promising area of translational neurobiology whose therapeutic relevance may extend far beyond diseases for which drugs have already been developed. [111][112][113][114]
Biological activity
[edit]Sigma-1 receptor
[edit]| Compound | Ki (nM) | Action | Species | Ref |
|---|---|---|---|---|
| Progesterone | 268 | Antagonist | Guinea pig | [116][117] |
| Deoxycorticosterone | 938 | Unknown | Guinea pig | [116][117] |
| Testosterone | 1,014 | Unknown | Guinea pig | [116][117] |
| Pregnenolone | ND | Agonist | ND | ND |
| Pregnenolone sulfate | 3,198 | Agonist | Guinea pig | [116][117] |
| DHEA | 3,700 | Agonist | ? | [117] |
| DHEA-S | ND | Agonist | ND | ND |
| Corticosterone | 4,074 | Unknown | Guinea pig | [116] |
Therapeutic applications
[edit]
Anesthesia
[edit]Several synthetic neurosteroids have been used as sedatives for the purpose of general anaesthesia for carrying out surgical procedures. The best known of these are alphaxolone, alphadolone, hydroxydione, and minaxolone. The first of these to be introduced was hydroxydione, which is the esterified 21-hydroxy derivative of 5β-pregnanedione. Hydroxydione proved to be a useful anaesthetic drug with a good safety profile, but was painful and irritating when injected probably due to poor water solubility. This led to the development of newer neuroactive steroids. The next drug from this family to be marketed was a mixture of alphaxolone and alphadolone, known as Althesin. This was withdrawn from human use due to rare but serious toxic reactions, but is still used in veterinary medicine. The next neurosteroid anaesthetic introduced into human medicine was the newer drug minaxolone, which is around three times more potent than althesin and retains the favourable safety profile, without the toxicity problems seen with althesin. However this drug was also ultimately withdrawn, not because of problems in clinical use, but because animal studies suggested potential carcinogenicity and since alternative agents were available it was felt that the possible risk outweighed the benefit of keeping the drug on the market.
Ganaxolone
[edit]
The neurosteroid ganaxolone, an analog of the progesterone metabolite allopregnanolone, has been extensively investigated in animal models and is currently in clinical trials for the treatment of epilepsy. Neurosteroids, including ganaxolone have a broad spectrum of activity in animal models.[118] They may have advantages over other GABAA receptor modulators, notably benzodiazepines, in that tolerance does not appear to occur with extended use.[119][120]
A randomized, placebo controlled, 10-week phase 2 clinical trial of orally administered ganaxolone in adults with partial onset seizure demonstrated that the treatment is safe, well tolerated and efficacious.[10] The drug continued to demonstrate efficacy in a 104-week open label extension. Data from non-clinical studies suggest that ganaxolone may have low risk for use in pregnancy. In addition to use in the treatment of epilepsy, the drug has potential in the treatment of a broad range of neurological and psychiatric conditions. Proof-of-concept studies are currently underway in posttraumatic stress disorder and fragile X syndrome. Ganaxolone was approved for medical use in the United States in March 2022.
Catamenial epilepsy
[edit]Researchers have suggested the use of so-called "neurosteroid replacement therapy" as a way of treating catamenial epilepsy with neuroactive steroids such as ganaxolone during the period of the menstrual cycle when seizure frequency increases.[7] Micronized progesterone, which behaves reliably as a prodrug to allopregnanolone, has been suggested as a treatment for catamenial epilepsy in the same manner.[121]
Allopregnanolone
[edit]Allopregnanolone (SAGE-547) is under development as an intravenous therapy for the treatment of super-refractory status epilepticus, postpartum depression, and essential tremor.[122]
Other applications
[edit]4,16-Androstadien-3β-ol (PH94B, Aloradine) is a synthetic pheromone, or pherine, neurosteroid which is under investigation for the treatment of anxiety disorders in women.[20][21][123]
3β-Methoxypregnenolone (MAP-4343), or pregnenolone 3β-methyl ether, is a synthetic neuroactive steroid and pregnenolone derivative that interacts with microtubule-associated protein 2 (MAP2) in a similar manner to pregnenolone and is under development for potential clinical use for indications such as the treatment of brain and spinal cord injury and depressive disorders.[124][125][126][127]
Role in antidepressant action
[edit]Certain antidepressant drugs such as fluoxetine and fluvoxamine, which are generally thought to affect depression by acting as selective serotonin reuptake inhibitors (SSRIs), have also been found to increase the levels of certain neurosteroids at concentrations that are inactive in affecting the reuptake of serotonin in animal models.[128] The potential contribution of this steroidogenic action to their therapeutic effects is of considerable interest, particularly in light of evidence that neurosteroid levels are normalized in patients with depression following treatment.[129][130]
The 3α-hydroxysteroid dehydrogenase (3α-HSD) enzyme is induced by certain (SSRIs), including fluoxetine, fluvoxamine, sertraline, and paroxetine, as well as by certain other antidepressants like venlafaxine and mirtazapine, coinciding with their steroidogenic actions.[131][132][133][134] Enhancement of biosynthesis of inhibitory neurosteroids has been implicated in the antidepressant and anxiolytic effects of some of the SSRIs.[131]
Benzodiazepine effects on neurosteroids
[edit]Benzodiazepines may influence neurosteroid metabolism by virtue of their actions on translocator protein (TSPO; "peripheral benzodiazepine receptor").[135] The pharmacological actions of benzodiazepines at the GABAA receptor are similar to those of neurosteroids, although the localization of benzodiazepine and neurosteroid-sensitive GABAA receptor subtypes vary.[136] Factors which affect the ability of individual benzodiazepines to alter neurosteroid levels may depend upon whether the individual benzodiazepine drug interacts with TSPO. Some benzodiazepines may also inhibit neurosteroidogenic enzymes reducing neurosteroid synthesis.[137]
See also
[edit]References
[edit]- 1 2 Majewska, M. D. (1992). "Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance". Progress in Neurobiology. 38 (4): 379–395. doi:10.1016/0301-0082(92)90025-a. ISSN 0301-0082. PMID 1349441.
- ↑ Lan NC, Gee KW (December 1994). "Neuroactive steroid actions at the GABAA receptor". Hormones and Behavior. 28 (4): 537–44. doi:10.1006/hbeh.1994.1052. PMID 7729823. S2CID 40697424.
- 1 2 3 4 5 6 Reddy DS (2010). "Neurosteroids". Sex Differences in the Human Brain, their Underpinnings and Implications. Progress in Brain Research. Vol. 186. pp. 113–37. doi:10.1016/B978-0-444-53630-3.00008-7. ISBN 9780444536303. PMC 3139029. PMID 21094889.
- ↑ Reddy DS, Rogawski MA (2012). "Neurosteroids — Endogenous Regulators of Seizure Susceptibility and Role in the Treatment of Epilepsy". In Noebels JL, Avoli M, Rogawski MA, et al. (eds.). Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US). National Center for Biotechnology Information (US). PMID 22787590.
- ↑ Paul, S. M.; Purdy, R. H. (1 March 1992). "Neuroactive steroids". FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 6 (6): 2311–2322. Bibcode:1992FASEJ...6.2311P. doi:10.1096/fasebj.6.6.1347506. ISSN 0892-6638. PMID 1347506.
- 1 2 Srivastava DP, Waters EM, Mermelstein PG, Kramár EA, Shors TJ, Liu F (November 2011). "Rapid estrogen signaling in the brain: implications for the fine-tuning of neuronal circuitry". The Journal of Neuroscience. 31 (45): 16056–63. doi:10.1523/JNEUROSCI.4097-11.2011. PMC 3245715. PMID 22072656.
- 1 2 Reddy DS, Rogawski MA (April 2009). "Neurosteroid replacement therapy for catamenial epilepsy". Neurotherapeutics. 6 (2): 392–401. doi:10.1016/j.nurt.2009.01.006. PMC 2682439. PMID 19332335.
- ↑ Morrow AL (October 2007). "Recent developments in the significance and therapeutic relevance of neuroactive steroids--Introduction to the special issue". Pharmacology & Therapeutics. 116 (1): 1–6. doi:10.1016/j.pharmthera.2007.04.003. PMC 2047816. PMID 17531324.
- ↑ Dubrovsky BO (February 2005). "Steroids, neuroactive steroids and neurosteroids in psychopathology". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29 (2): 169–92. doi:10.1016/j.pnpbp.2004.11.001. PMID 15694225. S2CID 36197603.
- 1 2 Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (January 2013). "Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)". Epilepsy Research. 103 (1): 2–30. doi:10.1016/j.eplepsyres.2012.10.001. PMID 23219031.
- ↑ Rougé-Pont F, Mayo W, Marinelli M, Gingras M, Le Moal M, Piazza PV (July 2002). "The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens". The European Journal of Neuroscience. 16 (1): 169–73. doi:10.1046/j.1460-9568.2002.02084.x. PMID 12153544. S2CID 9953445.
- 1 2 3 Frye CA (December 2009). "Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions". Psychoneuroendocrinology. 34 (Suppl 1): S143-61. doi:10.1016/j.psyneuen.2009.07.005. PMC 2898141. PMID 19656632.
- ↑ Pinna G, Costa E, Guidotti A (February 2005). "Changes in brain testosterone and allopregnanolone biosynthesis elicit aggressive behavior". Proceedings of the National Academy of Sciences of the United States of America. 102 (6): 2135–40. Bibcode:2005PNAS..102.2135P. doi:10.1073/pnas.0409643102. PMC 548579. PMID 15677716.
- ↑ Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J (October 2012). "Steroid hormones and sleep regulation". Mini Reviews in Medicinal Chemistry. 12 (11): 1040–8. doi:10.2174/138955712802762167. PMID 23092405.
- ↑ Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG (February 2014). "Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain". Progress in Neurobiology. 113: 70–8. doi:10.1016/j.pneurobio.2013.07.004. PMID 23948490. S2CID 207407077.
- ↑ Hénin J, Salari R, Murlidaran S, Brannigan G (May 2014). "A predicted binding site for cholesterol on the GABAA receptor". Biophysical Journal. 106 (9): 1938–1949. Bibcode:2014BpJ...106.1938H. doi:10.1016/j.bpj.2014.03.024. PMC 4017285. PMID 24806926.
- ↑ Levitan I, Singh DK, Rosenhouse-Dantsker A (2014). "Cholesterol binding to ion channels". Frontiers in Physiology. 5: 65. doi:10.3389/fphys.2014.00065. PMC 3935357. PMID 24616704.
- ↑ Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, et al. (October 2013). "The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors". The Journal of Neuroscience. 33 (44): 17290–17300. doi:10.1523/JNEUROSCI.2619-13.2013. PMC 3812502. PMID 24174662.
- ↑ Hawkes CH, Doty RL (12 February 2009). The Neurology of Olfaction. Cambridge University Press. pp. 37–. ISBN 978-0-521-68216-9.
- 1 2 Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL (1994). "The human vomeronasal system". Psychoneuroendocrinology. 19 (5–7): 673–86. doi:10.1016/0306-4530(94)90049-3. PMID 7938363. S2CID 36129626.
- 1 2 Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L (June 2014). "Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder". The American Journal of Psychiatry. 171 (6): 675–82. doi:10.1176/appi.ajp.2014.12101342. PMID 24700254. S2CID 38510058.
- ↑ Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD (September 2011). "Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence". Neuroscience. 191: 78–90. doi:10.1016/j.neuroscience.2011.06.076. PMID 21756978. S2CID 26396652.
- ↑ Baulieu E, Schumacher M (2000). "Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination". Steroids. 65 (10–11): 605–12. doi:10.1016/s0039-128x(00)00173-2. PMID 11108866. S2CID 14952168.
- ↑ Thomas P, Pang Y (2012). "Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells". Neuroendocrinology. 96 (2): 162–71. doi:10.1159/000339822. PMC 3489003. PMID 22687885.
- ↑ Agís-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A (September 2006). "Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis". Proceedings of the National Academy of Sciences of the United States of America. 103 (39): 14602–7. Bibcode:2006PNAS..10314602A. doi:10.1073/pnas.0606544103. PMC 1600006. PMID 16984997.
- ↑ Mellon SH, Griffin LD (2002). "Neurosteroids: biochemistry and clinical significance". Trends in Endocrinology and Metabolism. 13 (1): 35–43. doi:10.1016/S1043-2760(01)00503-3. PMID 11750861. S2CID 11605131.
- ↑ Benarroch EE (March 2007). "Neurosteroids: endogenous modulators of neuronal excitability and plasticity". Neurology. 68 (12): 945–7. doi:10.1212/01.wnl.0000257836.09570.e1. PMID 17372131. S2CID 219216099.
- ↑ Vallée M, Mayo W, Koob GF, Le Moal M (2001). "Neurosteroids in learning and memory processes". Neurosteroids and Brain Function. International Review of Neurobiology. Vol. 46. pp. 273–320. doi:10.1016/s0074-7742(01)46066-1. ISBN 9780123668462. PMID 11599303.
- 1 2 Engel SR, Grant KA (2001). "Neurosteroids and behavior". Neurosteroids and Brain Function. International Review of Neurobiology. Vol. 46. pp. 321–48. doi:10.1016/S0074-7742(01)46067-3. ISBN 9780123668462. PMID 11599304.
- 1 2 King SR (2008). "Emerging roles for neurosteroids in sexual behavior and function". Journal of Andrology. 29 (5): 524–33. doi:10.2164/jandrol.108.005660. PMID 18567641.
- ↑ Joshi S, Rajasekaran K, Kapur J (June 2013). "GABAergic transmission in temporal lobe epilepsy: the role of neurosteroids". Experimental Neurology. 244: 36–42. doi:10.1016/j.expneurol.2011.10.028. PMC 3319002. PMID 22101060.
- 1 2 Girdler SS, Klatzkin R (October 2007). "Neurosteroids in the context of stress: implications for depressive disorders". Pharmacology & Therapeutics. 116 (1): 125–39. doi:10.1016/j.pharmthera.2007.05.006. PMC 2650267. PMID 17597217.
- 1 2 Bali A, Jaggi AS (January 2014). "Multifunctional aspects of allopregnanolone in stress and related disorders". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 48: 64–78. doi:10.1016/j.pnpbp.2013.09.005. PMID 24044974. S2CID 21399549.
- ↑ Gunn BG, Cunningham L, Mitchell SG, Swinny JD, Lambert JJ, Belelli D (January 2015). "GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response". Frontiers in Neuroendocrinology. 36: 28–48. doi:10.1016/j.yfrne.2014.06.001. PMC 4349499. PMID 24929099.
- 1 2 Bäckström T, Andersson A, Andreé L, Birzniece V, Bixo M, Björn I, Haage D, Isaksson M, Johansson IM, Lindblad C, Lundgren P, Nyberg S, Odmark IS, Strömberg J, Sundström-Poromaa I, Turkmen S, Wahlström G, Wang M, Wihlbäck AC, Zhu D, Zingmark E (December 2003). "Pathogenesis in menstrual cycle-linked CNS disorders". Annals of the New York Academy of Sciences. 1007 (1): 42–53. Bibcode:2003NYASA1007...42B. doi:10.1196/annals.1286.005. PMID 14993039. S2CID 20995334.
- ↑ Guille C, Spencer S, Cavus I, Epperson CN (July 2008). "The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment". Epilepsy & Behavior. 13 (1): 12–24. doi:10.1016/j.yebeh.2008.02.004. PMC 4112568. PMID 18346939.
- ↑ Finocchi C, Ferrari M (May 2011). "Female reproductive steroids and neuronal excitability". Neurological Sciences. 32 (Suppl 1): S31-5. doi:10.1007/s10072-011-0532-5. PMID 21533709. S2CID 8885335.
- ↑ Genazzani AR, Bernardi F, Monteleone P, Luisi S, Luisi M (2000). "Neuropeptides, neurotransmitters, neurosteroids, and the onset of puberty". Annals of the New York Academy of Sciences. 900 (1): 1–9. Bibcode:2000NYASA.900....1G. doi:10.1111/j.1749-6632.2000.tb06210.x. PMID 10818386. S2CID 19302118.
- ↑ Melcangi RC, Panzica G, Garcia-Segura LM (September 2011). "Neuroactive steroids: focus on human brain". Neuroscience. 191: 1–5. doi:10.1016/j.neuroscience.2011.06.024. hdl:10261/61590. PMID 21704130. S2CID 55704799.
- ↑ Andréen L, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström T (August 2006). "Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone". Psychopharmacology. 187 (2): 209–21. doi:10.1007/s00213-006-0417-0. PMID 16724185. S2CID 1933116.
- 1 2 Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, Andréen L, Ossewaarde L, van Wingen GA, Turkmen S, Bengtsson SK (September 2011). "Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons". Neuroscience. 191: 46–54. doi:10.1016/j.neuroscience.2011.03.061. PMID 21600269. S2CID 38928854.
- 1 2 Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T (September 2009). "Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators". Psychoneuroendocrinology. 34 (8): 1121–32. doi:10.1016/j.psyneuen.2009.02.003. PMID 19272715. S2CID 22259026.
- 1 2 Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G (February 2014). "Allopregnanolone and mood disorders". Progress in Neurobiology. 113: 88–94. doi:10.1016/j.pneurobio.2013.07.005. PMID 23978486. S2CID 207407084.
- ↑ Bortolato, Marco; Pinna, Graziano (January 2026). "Charting the emerging neurosteroid landscape in neuropsychiatry". Neuroscience and Biobehavioral Reviews. 180 106494. doi:10.1016/j.neubiorev.2025.106494. ISSN 1873-7528. PMID 41308966.
- ↑ Pinna, Graziano; Bortolato, Marco (December 2025). "The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives". Neuroscience and Biobehavioral Reviews. 179 106438. doi:10.1016/j.neubiorev.2025.106438. ISSN 1873-7528. PMC 12959350. PMID 41777158.
- ↑ Walton, Najah L.; Maguire, Jamie L. (2025). "Neurosteroids: a lifelong impact on brain health". Frontiers in Behavioral Neuroscience. 19 1644615. doi:10.3389/fnbeh.2025.1644615. ISSN 1662-5153. PMC 12518332. PMID 41098637.
- ↑ Fedotcheva, Tatiana A.; Shimanovsky, Nikolay L. (23 June 2025). "Neurosteroids Progesterone and Dehydroepiandrosterone: Molecular Mechanisms of Action in Neuroprotection and Neuroinflammation". Pharmaceuticals. 18 (7). Basel, Switzerland: 945. doi:10.3390/ph18070945. ISSN 1424-8247. PMC 12298252. PMID 40732235.
- ↑ Lloyd-Evans, Emyr; Waller-Evans, Helen (23 September 2020). "Biosynthesis and signalling functions of central and peripheral nervous system neurosteroids in health and disease". Essays in Biochemistry. 64 (3): 591–606. doi:10.1042/EBC20200043. ISSN 1744-1358. PMC 7517341. PMID 32756865.
- ↑ Beall, D.; Reichstein, T. (September 1938). "Isolation of Progesterone and Allopregnanolone from the Adrenal". Nature. 142 (3593). Nature Publishing Group: 479. Bibcode:1938Natur.142..479B. doi:10.1038/142479b0. ISSN 1476-4687.
- ↑ Selye, Hans (1 January 1941). "Anesthetic Effect of Steroid Hormones.∗". Proceedings of the Society for Experimental Biology and Medicine. 46 (1). SAGE Publications: 116–121. doi:10.3181/00379727-46-11907. ISSN 0037-9727.
- ↑ Corpéchot, C.; Robel, P.; Axelson, M.; Sjövall, J.; Baulieu, E. E. (August 1981). "Characterization and measurement of dehydroepiandrosterone sulfate in rat brain". Proceedings of the National Academy of Sciences of the United States of America. 78 (8): 4704–4707. Bibcode:1981PNAS...78.4704C. doi:10.1073/pnas.78.8.4704. ISSN 0027-8424. PMC 320231. PMID 6458035.
- ↑ Harrison, N. L.; Simmonds, M. A. (10 December 1984). "Modulation of the GABA receptor complex by a steroid anaesthetic". Brain Research. 323 (2): 287–292. doi:10.1016/0006-8993(84)90299-3. ISSN 0006-8993. PMID 6098342.
- ↑ Majewska, M. D.; Bisserbe, J. C.; Eskay, R. L. (22 July 1985). "Glucocorticoids are modulators of GABAA receptors in brain". Brain Research. 339 (1): 178–182. doi:10.1016/0006-8993(85)90641-9. ISSN 0006-8993. PMID 2992695.
- ↑ Majewska, M. D.; Harrison, N. L.; Schwartz, R. D.; Barker, J. L.; Paul, S. M. (23 May 1986). "Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor". Science. 232 (4753). New York, N.Y.: 1004–1007. doi:10.1126/science.2422758. ISSN 0036-8075. PMID 2422758.
- ↑ Majewska, M. D.; Schwartz, R. D. (24 February 1987). "Pregnenolone-sulfate: an endogenous antagonist of the gamma-aminobutyric acid receptor complex in brain?". Brain Research. 404 (1–2): 355–360. doi:10.1016/0006-8993(87)91394-1. ISSN 0006-8993. PMID 3032339.
- ↑ Walerus (1987), pdf version of the 1987 review article by Maria Dorota Majewska published in Integrative Psychiatry. (PDF), retrieved 20 November 2026
- ↑ Corpéchot, C.; Robel, P.; Axelson, M.; Sjövall, J.; Baulieu, E. E. (August 1981). "Characterization and measurement of dehydroepiandrosterone sulfate in rat brain". Proceedings of the National Academy of Sciences of the United States of America. 78 (8): 4704–4707. Bibcode:1981PNAS...78.4704C. doi:10.1073/pnas.78.8.4704. ISSN 0027-8424. PMC 320231. PMID 6458035.
- ↑ Robel, P.; Baulieu, E. E. (1985). "Neuro-steroids: 3?-hydroxy-?(5)-derivatives in the rodent brain". Neurochemistry International. 7 (6): 953–958. doi:10.1016/0197-0186(85)90143-3. ISSN 0197-0186. PMID 20493007.
- ↑ Robel, P.; Bourreau, E.; Corpéchot, C.; Dang, D. C.; Halberg, F.; Clarke, C.; Haug, M.; Schlegel, M. L.; Synguelakis, M.; Vourch, C. (1987). "Neuro-steroids: 3 beta-hydroxy-delta 5-derivatives in rat and monkey brain". Journal of Steroid Biochemistry. 27 (4–6): 649–655. doi:10.1016/0022-4731(87)90133-6. ISSN 0022-4731. PMID 2961940.
- ↑ Baulieu, Etienne-Emile; Robel, Paul; Vatier, Oliver; Haug, Marc; Le Goascogne, Claude; Bourreau, Eliane (1987), Fuxe, Kjell; Agnati, Luigi F. (eds.), "Neurosteroids: Pregnenolone and Dehydroepiandrosterone in the Brain", Receptor-Receptor Interactions: A New Intramembrane Integrative Mechanism, London: Palgrave Macmillan UK, pp. 89–104, doi:10.1007/978-1-349-08949-9_9, ISBN 978-1-349-08949-9, retrieved 20 November 2026
{{citation}}: CS1 maint: work parameter with ISBN (link) - ↑ Majewska, M. D. (15 November 1987). "Steroids and brain activity. Essential dialogue between body and mind". Biochemical Pharmacology. 36 (22): 3781–3788. doi:10.1016/0006-2952(87)90437-0. ISSN 0006-2952. PMID 2825703.
- ↑ Baulieu, E. E.; Robel, P. (20 November 1990). "Neurosteroids: a new brain function?". The Journal of Steroid Biochemistry and Molecular Biology. 37 (3): 395–403. doi:10.1016/0960-0760(90)90490-c. ISSN 0960-0760. PMID 2257243.
- ↑ Majewska, M. D. (1992). "Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance". Progress in Neurobiology. 38 (4): 379–395. doi:10.1016/0301-0082(92)90025-a. ISSN 0301-0082. PMID 1349441.
- ↑ Baulieu, E. E. (1997). "Neurosteroids: of the nervous system, by the nervous system, for the nervous system". Recent Progress in Hormone Research. 52: 1–32. ISSN 0079-9963. PMID 9238846.
- ↑ Baulieu, E. E. (1997). "Neurosteroids: of the nervous system, by the nervous system, for the nervous system". Recent Progress in Hormone Research. 52: 1–32. ISSN 0079-9963. PMID 9238846.
- ↑ Baulieu, E. E. (November 1998). "Neurosteroids: a novel function of the brain". Psychoneuroendocrinology. 23 (8): 963–987. doi:10.1016/s0306-4530(98)00071-7. ISSN 0306-4530. PMID 9924747.
- ↑ Baulieu, E. E.; Robel, P.; Schumacher, M. (2001). "Neurosteroids: beginning of the story". Neurosteroids and Brain Function. International Review of Neurobiology. Vol. 46. pp. 1–32. doi:10.1016/s0074-7742(01)46057-0. ISBN 978-0-12-366846-2. ISSN 0074-7742. PMID 11599297.
- ↑ "Bench-to-bedside: NIMH research leads to brexanolone, first-ever drug specifically for postpartum depression | National Institutes of Health (NIH)". www.nih.gov. Retrieved 20 November 2026.
- ↑ "Basic Research Powers the First Medication for Postpartum Depression - National Institute of Mental Health (NIMH)". www.nimh.nih.gov. 14 May 2024. Retrieved 20 November 2026.
- ↑ "From Neurobiology to Novel Medications: A Principled Approach to Translation | - Search Results - PubMed". Retrieved 20 November 2026.
- ↑ Consortium for Preclinical Psychiatric Research (February 2026). "Of mice, molecules and mental health: establishment of the consortium for preclinical psychiatric research to find solutions to the translational gap". Molecular Psychiatry. 31 (2): 1167–1170. doi:10.1038/s41380-025-03361-x. ISSN 1476-5578. PMID 41315813.
- ↑ Mortensen, Martin; Bright, Damian P.; Fagotti, Juliane; Dorovykh, Valentina; Cerna, Barbora; Smart, Trevor G. (10 July 2025). "Forty Years Searching for Neurosteroid Binding Sites on GABAA Receptors". Neuroscience. 578: 6–24. doi:10.1016/j.neuroscience.2024.06.002. ISSN 1873-7544. PMID 38852898.
- ↑ Hosie, Alastair M.; Wilkins, Megan E.; da Silva, Helena M. A.; Smart, Trevor G. (23 November 2006). "Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites". Nature. 444 (7118): 486–489. doi:10.1038/nature05324. ISSN 1476-4687. PMID 17108970.
- ↑ Chen, Zi-Wei; Manion, Brad; Townsend, R. Reid; Reichert, David E.; Covey, Douglas F.; Steinbach, Joe Henry; Sieghart, Werner; Fuchs, Karoline; Evers, Alex S. (September 2012). "Neurosteroid analog photolabeling of a site in the third transmembrane domain of the β3 subunit of the GABA(A) receptor". Molecular Pharmacology. 82 (3): 408–419. doi:10.1124/mol.112.078410. ISSN 1521-0111. PMC 3422701. PMID 22648971.
- ↑ Sugasawa, Yusuke; Cheng, Wayland Wl; Bracamontes, John R.; Chen, Zi-Wei; Wang, Lei; Germann, Allison L.; Pierce, Spencer R.; Senneff, Thomas C.; Krishnan, Kathiresan; Reichert, David E.; Covey, Douglas F.; Akk, Gustav; Evers, Alex S. (21 September 2020). "Site-specific effects of neurosteroids on GABAA receptor activation and desensitization". eLife. 9 e55331. doi:10.7554/eLife.55331. ISSN 2050-084X. PMC 7532004. PMID 32955433.
- ↑ Legesse, Dagimhiwat H.; Fan, Chen; Teng, Jinfeng; Zhuang, Yuxuan; Howard, Rebecca J.; Noviello, Colleen M.; Lindahl, Erik; Hibbs, Ryan E. (22 August 2023). "Structural insights into opposing actions of neurosteroids on GABAA receptors". Nature Communications. 14 (1): 5091. doi:10.1038/s41467-023-40800-1. ISSN 2041-1723. PMC 10444788. PMID 37607940.
- ↑ Cite error: There are
<ref>tags on this page without content in them (see the help page). - ↑ Pinna, Graziano (2020). "Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next?". Frontiers in Endocrinology. 11 236. doi:10.3389/fendo.2020.00236. ISSN 1664-2392. PMC 7240001. PMID 32477260.
- ↑ Gordon, Joshua A. (1 June 2019). "From Neurobiology to Novel Medications: A Principled Approach to Translation". The American Journal of Psychiatry. 176 (6): 425–427. doi:10.1176/appi.ajp.2019.19040386. ISSN 1535-7228. PMID 31154816.
- ↑ Rupprecht, Rainer; Schüle, Cornelius; Gudermann, Thomas (March 2026). "Neuroactive steroids for the treatment of depression and anxiety: gaps and promises". European Archives of Psychiatry and Clinical Neuroscience. 276 (2): 405–406. doi:10.1007/s00406-026-02196-z. ISSN 1433-8491. PMC 12953314. PMID 41579166.
- ↑ Pinna, Graziano (November 2020). "Allopregnanolone (1938-2019): A trajectory of 80 years of outstanding scientific achievements". Neurobiology of Stress. 13 100246. doi:10.1016/j.ynstr.2020.100246. ISSN 2352-2895. PMC 7451447. PMID 32875009.
- ↑ Paul, Steven M.; Pinna, Graziano; Guidotti, Alessandro (May 2020). "Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective". Neurobiology of Stress. 12 100215. doi:10.1016/j.ynstr.2020.100215. ISSN 2352-2895. PMC 7231972. PMID 32435665.
- ↑ https://pdf.benchchem.com/1218/The_Discovery_and_Development_of_Neuroactive_Steroids_A_Technical_Guide.pdf
- ↑ Paul, S. M.; Purdy, R. H. (March 1992). "Neuroactive steroids". FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 6 (6): 2311–2322. Bibcode:1992FASEJ...6.2311P. doi:10.1096/fasebj.6.6.1347506. ISSN 0892-6638. PMID 1347506.
- ↑ Uzunova, V.; Sheline, Y.; Davis, J. M.; Rasmusson, A.; Uzunov, D. P.; Costa, E.; Guidotti, A. (17 March 1998). "Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine". Proceedings of the National Academy of Sciences of the United States of America. 95 (6): 3239–3244. Bibcode:1998PNAS...95.3239U. doi:10.1073/pnas.95.6.3239. ISSN 0027-8424. PMC 19726. PMID 9501247.
- ↑ Liu, Lu; Li, Yubao; Mao, Tian; Li, Ting; Zhu, Ruilou; Cong, Xuhui; Jiang, Lulu; Sun, Mingyang; Zhang, Jiaqiang (September 2025). "Neuroactive Steroids Hold Promise as Innovative Anesthetics". Drug Development Research. 86 (6) e70137. doi:10.1002/ddr.70137. ISSN 1098-2299. PMID 40801291.
- ↑ Meltzer-Brody, Samantha; Colquhoun, Helen; Riesenberg, Robert; Epperson, C. Neill; Deligiannidis, Kristina M.; Rubinow, David R.; Li, Haihong; Sankoh, Abdul J.; Clemson, Christine; Schacterle, Amy; Jonas, Jeffrey; Kanes, Stephen (22 September 2018). "Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials". Lancet. 392 (10152). London, England: 1058–1070. doi:10.1016/S0140-6736(18)31551-4. ISSN 1474-547X. PMID 30177236.
- ↑ Morrison, K. E.; Cole, A. B.; Thompson, S. M.; Bale, T. L. (September 2019). "Brexanolone for the treatment of patients with postpartum depression". Drugs of Today. 55 (9). Barcelona, Spain : 1998: 537–544. doi:10.1358/dot.2019.55.9.3040864. ISSN 1699-3993. PMC 8033597. PMID 31584571.
{{cite journal}}: CS1 maint: location (link) - ↑ Commissioner, Office of the (9 August 2024). "FDA Approves First Oral Treatment for Postpartum Depression". FDA. Retrieved 20 November 2026.
- ↑ https://www.pmda.go.jp/files/000283315.pdf
- ↑ Terao, Itsuki (July 2026). "Durability of zuranolone in postpartum depression versus major depressive disorder". Psychiatry and Clinical Neurosciences. 80 (7): 630. doi:10.1111/pcn.70011. ISSN 1440-1819. PMID 41424436.
- ↑ Zorumski, Charles F.; Covey, Douglas F.; Izumi, Yukitoshi; Evers, Alex S.; Maguire, Jamie L.; Mennerick, Steven J. (May 2025). "New directions in neurosteroid therapeutics in neuropsychiatry". Neuroscience and Biobehavioral Reviews. 172 106119. doi:10.1016/j.neubiorev.2025.106119. ISSN 1873-7528. PMC 13044583. PMID 40127877.
- ↑ Lin, Yu-Wei; Tu, Yu-Kang; Hung, Kuo-Chuan; Liang, Chih-Sung; Tseng, Ping-Tao; Lin, Pao-Yen; Chia-Cheng Lai, Edward; Hsu, Chih-Wei (December 2023). "Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses". eClinicalMedicine. 66 102308. doi:10.1016/j.eclinm.2023.102308. ISSN 2589-5370. PMC 10690540. PMID 38045802.
- ↑ "Basic Research Powers the First Medication for Postpartum Depression - National Institute of Mental Health (NIMH)". www.nimh.nih.gov. 14 May 2024. Retrieved 20 November 2026.
- ↑ Commissioner, Office of the (9 August 2024). "FDA Approves First Oral Treatment for Postpartum Depression". FDA. Retrieved 20 November 2026.
- ↑ Gonzalez-Torres, Christina; Sharma, Verinder (November 2026). "Profiling zuranolone as a treatment option for postpartum depression". Expert Review of Neurotherapeutics. 26 (11): 1041–1051. doi:10.1080/14737175.2026.2733192. ISSN 1744-8360. PMID 42750260.
- ↑ Zavaleta-Monestel, Esteban; Herrera-Jiménez, Luis Guillermo; González-Aguilar, Katherine; Mora-Jiménez, Jeaustin; Millán González, Ricardo (August 2026). "Zuranolone in Postpartum Depression: Mechanistic Innovation, Clinical Evidence, and Translational Uncertainty". Cureus. 18 (8) e114673. doi:10.7759/cureus.114673. ISSN 2168-8184. PMC 13580881. PMID 42751664.
- ↑ Theroux, Jenna D.; Carter, Cameron; Sayed, Farah; Prajdic, Julia (1 November 2026). "Evolving treatment approaches for postpartum depression: The role of neuroactive steroids". The Nurse Practitioner. 51 (11): 28–32. doi:10.1097/01.NPR.0000000000000491. ISSN 1538-8662. PMID 42945487.
- ↑ Stewart, Anne Louise; Towers, Eleanor Blair; Wenzel, Elizabeth S.; Payne, Jennifer L. (June 2026). "Pharmacotherapeutic approaches to treating postpartum depression: a focus on GABAA receptor positive allosteric modulators". Expert Opinion on Pharmacotherapy. 27 (8): 689–695. doi:10.1080/14656566.2026.2675004. ISSN 1744-7666. PMID 42150157.
- ↑ Uyar, Aslihan; Gonul, Ali Saffet (2025). "New and emerging pharmacologic treatments for MDD". Frontiers in Psychiatry. 16 1621887. doi:10.3389/fpsyt.2025.1621887. ISSN 1664-0640. PMC 12371239. PMID 40859935.
- ↑ Kato, Masaki; Nakagome, Kazuyuki; Baba, Takamichi; Sonoyama, Takuhiro; Fukuju, Hiroki; Shimizu, Ryosuke; Gomez, Juan Carlos; Motomiya, Tomoko; Inoue, Takeshi (March 2026). "Safety and efficacy of zuranolone in Japanese adults with major depressive disorder: An open-label, repeated-treatment part of a Phase 3 clinical trial". PCN Reports: Psychiatry and Clinical Neurosciences. 5 (1) e70302. doi:10.1002/pcn5.70302. ISSN 2769-2558. PMC 12917863. PMID 41727674.
- ↑ https://www.shionogi.com/content/dam/shionogi/global/news/pdf/2025/12%E6%9C%88/E_20251222.pdf
- ↑ Li, Zejun; Wu, Qiuxia; Peng, Pu; Wu, Min; Liu, Shouhuan; Liu, Tieqiao (January 2024). "Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis". Psychiatry Research. 331 115640. doi:10.1016/j.psychres.2023.115640. ISSN 1872-7123. PMID 38029628.
- ↑ Liu, Jianmin; Hong, Limian; Qian, Yudie; Chen, Rui; Lin, Weiwei (1 January 2026). "Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder". Journal of Affective Disorders. 392 120158. doi:10.1016/j.jad.2025.120158. ISSN 1573-2517. PMID 40876640.
- ↑ Riebel, Marco; Brunner, Lisa-Marie; Nothdurfter, Caroline; Wein, Simon; Schwarzbach, Jens; Liere, Philippe; Schumacher, Michael; Rupprecht, Rainer (September 2025). "Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression". European Archives of Psychiatry and Clinical Neuroscience. 275 (6): 1581–1591. doi:10.1007/s00406-024-01843-7. ISSN 1433-8491. PMC 12500809. PMID 38976049.
- ↑ Bozzatello, Paola; Novelli, Roberta; Schisano, Rebecca; Brasso, Claudio; Rocca, Paola; Bellino, Silvio (30 April 2025). "New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?". Pharmaceuticals. 18 (5). Basel, Switzerland: 665. doi:10.3390/ph18050665. ISSN 1424-8247. PMC 12114474. PMID 40430486.
- ↑ Belelli, Delia; Hogenkamp, Derk; Gee, Kelvin W.; Lambert, Jeremy J. (May 2020). "Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor". Neurobiology of Stress. 12 100207. doi:10.1016/j.ynstr.2019.100207. ISSN 2352-2895. PMC 7231973. PMID 32435660.
- ↑ Uchida, Hiroyuki; Gobbi, Gabriella; Zohar, Joseph; Young, Allan H.; Rujescu, Dan; Huang, Ming-Chyi; Sundram, Suresh; Atwoli, Lukoye; Vukovic, Jana; Ikeda, Kazutaka (10 August 2026). "Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade". The International Journal of Neuropsychopharmacology. 29 (8) pyag023. doi:10.1093/ijnp/pyag023. ISSN 1469-5111. PMC 13499527. PMID 42096531.
- ↑ Arslan, Ayla (2026). Insights into Dysregulated GABAergic Synapses and Depression: A Complex and Evolving Relationship. Advances in Experimental Medicine and Biology. Vol. 1502. pp. 289–315. doi:10.1007/978-981-95-6872-7_17. ISSN 0065-2598. PMID 42036574.
- ↑ Dargan, Tauryn L.; Walton, Najah L.; Maguire, Jamie L. (15 December 2026). "Potential of Neurosteroids for Precision Medicine in Psychiatry". Biological Psychiatry. 100 (12): 1168–1180. doi:10.1016/j.biopsych.2026.07.009. ISSN 1873-2402. PMC 13761798. PMID 42480802.
- ↑ Bortolato, Marco; Pinna, Graziano (January 2026). "Charting the emerging neurosteroid landscape in neuropsychiatry". Neuroscience and Biobehavioral Reviews. 180 106494. doi:10.1016/j.neubiorev.2025.106494. ISSN 1873-7528. PMID 41308966.
- ↑ Pinna, Graziano; Bortolato, Marco (December 2025). "The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives". Neuroscience and Biobehavioral Reviews. 179 106438. doi:10.1016/j.neubiorev.2025.106438. ISSN 1873-7528. PMC 12959350. PMID 41777158.
- ↑ Mallick, Keya; Ruwatia, Ritika; Mondal, Amal C.; Banerjee, Sugato (12 March 2026). "Neurosteroids in Neurological and Psychiatric Disorders: Therapeutic Implications". CNS & Neurological Disorders Drug Targets. 25. doi:10.2174/0118715273411580251203115939. ISSN 1996-3181. PMID 41833033.
- ↑ Pinna, Graziano; Ponomareva, Olga; Stalcup, George L.; Rasmusson, Ann M. (May 2025). "Neuroactive steroids and the pathophysiology of PTSD: Biomarkers for treatment targeting". Neuroscience and Biobehavioral Reviews. 172 106085. doi:10.1016/j.neubiorev.2025.106085. ISSN 1873-7528. PMC 12160560. PMID 40024353.
- ↑ Maurice T, Urani A, Phan VL, Romieu P (2001). "The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities". Brain Res. Brain Res. Rev. 37 (1–3): 116–32. doi:10.1016/s0165-0173(01)00112-6. PMID 11744080. S2CID 44931783.
- 1 2 3 4 5 Su TP, London ED, Jaffe JH (1988). "Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems". Science. 240 (4849): 219–21. Bibcode:1988Sci...240..219S. doi:10.1126/science.2832949. PMID 2832949.
- 1 2 3 4 5 Takebayashi M, Hayashi T, Su TP (2004). "A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors". Pharmacopsychiatry. 37 (Suppl 3): S208–13. doi:10.1055/s-2004-832679. PMID 15547787. S2CID 260243232.
- ↑ Rogawski MA, Reddy DS, 2004. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho, J.M., Sankar, R., Cavazos, J. (Eds.), Epilepsy: Scientific Foundations of Clinical Practice. Marcel Dekker, New York, 2004;319-355.
- ↑ Kokate TG, Yamaguchi S, Pannell LK, Rajamani U, Carroll DM, Grossman AB, Rogawski MA (November 1998). "Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice". The Journal of Pharmacology and Experimental Therapeutics. 287 (2): 553–8. doi:10.1016/S0022-3565(24)37827-9. PMID 9808680.
- ↑ Reddy DS, Rogawski MA (December 2000). "Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself". The Journal of Pharmacology and Experimental Therapeutics. 295 (3): 1241–8. doi:10.1016/S0022-3565(24)39026-3. PMID 11082461.
- ↑ Devinsky O, Schachter S, Pacia S (1 January 2005). Complementary and Alternative Therapies for Epilepsy. Demos Medical Publishing. pp. 378–. ISBN 978-1-934559-08-6.
- ↑ "Brexanolone - Sage Therapeutics". AdisInsight. Springer Nature Switzerland AG.
- ↑ Griebel G, Holmes A (September 2013). "50 years of hurdles and hope in anxiolytic drug discovery" (PDF). Nature Reviews. Drug Discovery. 12 (9): 667–87. doi:10.1038/nrd4075. PMC 4176700. PMID 23989795.
- ↑ "Pregnenolone methyl ether - Mapreg". AdisInsight. Springer Nature Switzerland AG.
- ↑ Duchossoy Y, David S, Baulieu EE, Robel P (2011). "Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone". Brain Res. 1403: 57–66. doi:10.1016/j.brainres.2011.05.065. PMID 21704982. S2CID 42657539.
- ↑ Bianchi M, Baulieu EE (2012). "3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders". Proc. Natl. Acad. Sci. U.S.A. 109 (5): 1713–8. Bibcode:2012PNAS..109.1713B. doi:10.1073/pnas.1121485109. PMC 3277154. PMID 22307636.
- ↑ Baulieu ÉÉ (2015). "From steroid hormones to depressive states and senile dementias: New mechanistic, therapeutical and predictive approaches". Comptes Rendus Biologies. 338 (8–9): 613–6. doi:10.1016/j.crvi.2015.06.003. PMID 26251072.
- ↑ Pinna, Graziano; Costa, Erminio; Guidotti, Alessandro (24 January 2006). "Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake". Psychopharmacology. 186 (3): 362–372. doi:10.1007/s00213-005-0213-2. ISSN 0033-3158. PMID 16432684.
- ↑ Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (March 1998). "Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine". Proceedings of the National Academy of Sciences of the United States of America. 95 (6): 3239–44. Bibcode:1998PNAS...95.3239U. doi:10.1073/pnas.95.6.3239. PMC 19726. PMID 9501247.
- ↑ Pinna G, Costa E, Guidotti A (24 January 2006). "Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake". Psychopharmacology. 186 (3): 362–72. doi:10.1007/s00213-005-0213-2. PMID 16432684. S2CID 7799814.
- 1 2 Reddy, Doodipala Samba (2010). "Neurosteroids". Sex Differences in the Human Brain, their Underpinnings and Implications. Progress in Brain Research. Vol. 186. pp. 113–137. doi:10.1016/B978-0-444-53630-3.00008-7. ISBN 978-0-444-53630-3. ISSN 0079-6123. PMC 3139029. PMID 21094889.
- ↑ Griffin LD, Mellon SH (November 1999). "Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes". Proc. Natl. Acad. Sci. U.S.A. 96 (23): 13512–7. Bibcode:1999PNAS...9613512G. doi:10.1073/pnas.96.23.13512. PMC 23979. PMID 10557352.
- ↑ Pinna G (September 2010). "In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis". Behav Pharmacol. 21 (5–6): 438–50. doi:10.1097/FBP.0b013e32833d8ba0. PMC 2942072. PMID 20716970.
- ↑ Schüle C, Romeo E, Uzunov DP, Eser D, di Michele F, Baghai TC, Pasini A, Schwarz M, Kempter H, Rupprecht R (March 2006). "Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity". Mol. Psychiatry. 11 (3): 261–72. doi:10.1038/sj.mp.4001782. PMID 16344854. S2CID 21473462.
- ↑ Dhir A, Rogawski MA (April 2012). "Role of neurosteroids in the anticonvulsant activity of midazolam". British Journal of Pharmacology. 165 (8): 2684–91. doi:10.1111/j.1476-5381.2011.01733.x. PMC 3423249. PMID 22014182.
- ↑ Wang, Mingde (2011). "Neurosteroids and GABA-A Receptor Function". Frontiers in Endocrinology. 2: 44. doi:10.3389/fendo.2011.00044. ISSN 1664-2392. PMC 3356040. PMID 22654809.
- ↑ Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A (April 2002). "Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines" (pdf). Biological & Pharmaceutical Bulletin. 25 (4): 441–5. doi:10.1248/bpb.25.441. PMID 11995921.
Further reading
[edit]- Akk G, Shu HJ, Wang C, Steinbach JH, Zorumski CF, Covey DF, Mennerick S (December 2005). "Neurosteroid access to the GABAA receptor". The Journal of Neuroscience. 25 (50): 11605–13. doi:10.1523/JNEUROSCI.4173-05.2005. PMC 6726021. PMID 16354918.
- Wang JM, Johnston PB, Ball BG, Brinton RD (May 2005). "The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression". The Journal of Neuroscience. 25 (19): 4706–18. doi:10.1523/JNEUROSCI.4520-04.2005. PMC 6724768. PMID 15888646.
- Dong E, Matsumoto K, Uzunova V, Sugaya I, Takahata H, Nomura H, Watanabe H, Costa E, Guidotti A (February 2001). "Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation". Proceedings of the National Academy of Sciences of the United States of America. 98 (5): 2849–54. Bibcode:2001PNAS...98.2849D. doi:10.1073/pnas.051628598. PMC 30228. PMID 11226329.
- Melcangi RC, Celotti F, Martini L (March 1994). "Progesterone 5-alpha-reduction in neuronal and in different types of glial cell cultures: type 1 and 2 astrocytes and oligodendrocytes". Brain Research. 639 (2): 202–6. doi:10.1016/0006-8993(94)91731-0. PMID 8205473. S2CID 37105244.
- Corpéchot C, Robel P, Axelson M, Sjövall J, Baulieu EE (August 1981). "Characterization and measurement of dehydroepiandrosterone sulfate in rat brain". Proceedings of the National Academy of Sciences of the United States of America. 78 (8): 4704–7. Bibcode:1981PNAS...78.4704C. doi:10.1073/pnas.78.8.4704. PMC 320231. PMID 6458035.
- Reddy D, Rogawski MA (2012). "Neurosteroids — Endogenous regulators of seizure susceptibility and role in the treatment of epilepsy". In Noebels JL, Avoli M, Rogawski MA, et al. (eds.). Jasper's Basic Mechanisms of the Epilepsies (4th ed.). Bethesda (MD): National Center for Biotechnology Information. PMID 22787590.